SU-250
SU-400
TA-300
Test mix 325
TE-300
TE-250
TC-200
TP-100
DECA-300 (ND-300)
TRENMIX-200
DP-100
MAST-200
TrX-100
PRIMO-100
PROVI-100
Blend-500
Blend-375

Description:

Product Name : Bivalirudin
Trade Name:DPHE-PRO-ARG-PRO-GLY-GLY-GLY-GLY-ASN-GLY-ASP-PHE-GLU-GLU-LLE-PRO-GLU-GLU-TYR-LEU
CAS No.:128270-60-0
Molecular Formula: C98H138N24O33
Molecular Weight:2180.29g/mol
Purity : 98% HPLC
Appearance:  Lyophilized Powder
Typical use:Anticoagulants
Shelf Life :2 years
Payment Terms:T/T, Western Union, Money Gram
Storage:Refrigeration keep dry and away from light.

Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).

Bivalirudin is a kind of synthetic novel anticoagulants(DTI). It is the direct, specific and reversible inhibitor of thrombin.  Its anticoagulant ingredient is a kind of 20 peptides derived from hirudin. Bivalirudin can specifically bind with catalytic site and the anion binding site of whether thrombin that is in the blood circulation or thrombus-bound thrombin, thus directly inhibiting thrombin activity. And its role is characterized by short, reversible. Early clinical studies show that the anticoagulation treatment of bivalirudin is good. And the incidence of bleeding events is low. So its use is safer than traditional heparin therapy. It is mainly used for the prevention of angioplasty interventional treatment of ischemic complications of unstable angina pectoris before and after. 
 
Bivalirudin has a inhibitory effect on soluble and thrombus-bound thrombin in vitro. That effect cannot be affected by products that are released by platelet, and it can extend plasma activated partial thromboplastin time, thrombin time and prothrombin time of normal human with a dose-dependent manner. It is suitable for percutaneous coronary intervention (PCI) unstable angina.
Clinically experiments prove that bivalirudin is more effective than the current mainstream unfractionated heparin/low molecular weight heparin and platelet glycoprotein receptor antagonist in applications around PCI.


Application:
1. It can significantly reduce the incidence of bleeding in elective PCI patients. The total clinical outcome risk fell 14%.
2. It does not cause antibody-mediated thrombocytopenia.
3. Reversibly bind with thrombin. Short half-life. Hard to develop ischemic and hemorrhagic complications. 
4. It is not mainly excreted through the kidneys and can be safely used in patients with renal impairment.